Introduction
Less than one-third of patients who are candidates for allogeneic hematopoietic cell transplantation have an HLA-matched related donor. The remainder rely on unrelated adult donors or cord blood. After transplantation from unrelated donors (URDs), graft failure occurs rarely, but is more frequent after HLA-mismatched transplants, 1,2 T-cell depletion, 3 reduced intensity regimens and cord blood grafts. 4, 5 Other factors that contribute to graft failure include minimal earlier treatment, low numbers of CD34 þ cells in the graft and drug-related toxicity. 6, 7 Graft failure is life-threatening and usually results in infectious death. Therapeutic approaches include growth factor administration, 8 re-infusion of hematopoietic cells from the same or a different donor (with or without conditioning) [9] [10] [11] [12] and infusion of earlier stored autologous marrow. 13 Growth factors are usually ineffective in this setting; successful intervention requires infusion of additional hematopoietic cells.
Obtaining hematopoietic cells from the original or a different adult donor usually takes several weeks, exposing the patient to substantial prolongation of pancytopenia. Frozen autologous marrow provides a ready source of stem cells, but no formal recommendations exist for backup storage of autologous stem cells in patients undergoing unrelated transplantation. 14 The Cleveland Clinic has routinely performed 'backup' autologous harvest in patients with hematological malignancies and lymphomas without evidence of disease in their marrow and in CML patients with chronic phase disease before URD transplantation. We reviewed our use and analyzed the effectiveness of back-up marrow harvests over the last 14 years to determine the value of their routine collection.
Patients and methods

Patients
The Unified Transplant Database of the Cleveland Clinic Foundation was searched to identify patients who had backup marrows harvested from January 1995 through September 2008 and those who had these marrows infused. Recipients of unrelated adult or cord blood transplants with lymphoma without evidence of marrow disease, hematological malignancies in CR, and CML in chronic phase were harvested. Through 2001, patients had HLA matching at the Ag level for HLA-A, -B, and at the allele level for DRB1, and subsequently at the allele level for all loci, including -C. The schema developed by the CIBMTR and NMDP was used to categorize HLA matching between patients and unrelated adult donors. 15 Cords were matched at the Ag level for HLA-A and -B, and at the allele level for DRB1. Data were analyzed as of 1 March 2009.
Initial transplant
Adult URDs were identified through the National Marrow Donor Program. Patients received preparative regimens and GVHD prophylaxis according to several protocols. Engraftment was defined as PMN 4500/ml for 3 successive days and plts 420 000/ml independent of transfusions. Engraftment was monitored by following complete blood counts, chimerism studies and BM biopsies.
Statistical methods
Categorical variables are described as frequency counts and percentages, whereas continuous variables are summarized as the median and range.
Results
One hundred thirty recipients of unrelated transplants underwent backup BM collection from January 1995 through September 2008. Sixty-two patients who underwent myeloablative preparation and received unmanipulated marrow or PBSCs had marrow stored. Two of 20 patients (10%) who underwent fully ablative preparation and non-manipulated marrow transplantation from partially matched (n ¼ 17) or mismatched (n ¼ 3) URDs required reinfusion of stored autologous marrow; both were partially matched. None of the 42 patients with wellmatched donors required reinfusion. None of the 10 wellmatched patients who underwent T-cell depletion and myeloablative preparation required their backup marrow.
Stored marrow was infused in five of 24 patients (21%) receiving partially matched and four of 13 (31%) receiving mismatched unrelated grafts that had undergone T-cell depletion. The only patient who underwent reduced intensity preparation and received marrow (from a wellmatched URD) required an infusion of the stored marrow. None of the nine patients receiving peripheral blood cells after non-ablative regimens required stored marrow. Three of 11 patients who underwent ablative transplants using 4-5/6 HLA-matched cords required reinfusion. Two had nucleated cell doses p2 Â 10 7 /kg, and the third had a nucleated cell dose 43.5 Â 10 7 /kg. All fifteen (11%) patients who had their autologous marrows infused had graft failure. The characteristics of these 15 patients are shown in Table 1 . Peripheral blood counts, BM biopsy in all 15 patients, and chimerism studies in the 10 patients in whom these were performed were used to make the diagnosis of graft failure. None of these individuals showed evidence of persistence or relapse of their malignancy and none received conditioning before infusion of stored marrow.
Median time from original transplant to rescue autologous infusion was 1.1 months (range 0.7-7.6 months). Eight patients showed hematopoietic recovery after autologous marrow infusion. The median number of days to ANC4500 after infusion of the rescue autograft was 12 days (range 8-75 days). Five patients are alive and in CR 2-11.6 (median 7.6) years after backup infusion. Of these five, two subsequently underwent a second URD transplant and are alive and well at 11.6 and 5.3 years. One underwent a second fully ablative transplant and achieved complete donor chimerism; before the second allotransplant, only recipient cells were present. The other underwent a second non-myeloablative transplant and had recovery of only recipient cells. The three other patients survive in CR without repeat allogeneic transplant at 9.2, 7.7 and 2 years; chimerism studies were performed in two patients and show only recipient leukocytes. Three other patients who went on to a second myeloablative URD transplant died, two from relapse and the third from infection. Of the 10 patients who died after backup infusion, four died from relapse and six from infection 1 to 12 months from autologous rescue.
Discussion
Graft failure is a usually lethal complication of allogeneic transplantation. Treatment includes infusion of additional hematopoietic cells from the original URD (with or without further conditioning) or a second URD. Obtaining these cells, however, usually takes several weeks. Few data exist regarding the use of autologous rescue as treatment for graft failure after allogeneic transplant. Mehta et al.
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reported 10 patients who received backup autologous marrow for graft failure; six remained alive several months to years later. By contrast, a survey by the EBMT reported dismal outcomes after backup graft infusion.
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In our series, 15 of the 130 (11%) marrows collected were used. Eight patients achieved hematopoietic recovery and five (33%) obtained durable remission after autologous rescue alone or by allowing a bridge to a second allogeneic transplant. It is intriguing that three patients who received autologous rescue infusion and who did not receive a second allogeneic transplant and one who recovered with autologous cells after a second non-myeloablative transplant have remained in durable remissions. The mechanism of these durable remissions is not known. It is possible that immunological mechanisms responsible for graft failure might also generate a graft-versus-tumor effect. Clearly, our data show that autologous stored marrow can be an effective treatment for graft failure after URD transplantation.
It is therefore important to identify those patients whose risk of graft failure is sufficient to justify this procedure. Patients with well-matched URDs undergoing transplantation of unmanipulated hematopoietic cells or non-myeloablative transplantation with PBSCs did not require infusion of stored marrow and we do not recommend its use in those circumstances. By contrast, those receiving hematopoietic cells from partially matched or mismatched adult donors, particularly with T-cell depletion, or low cell doses of cord blood, are at risk of graft failure. Backup marrow harvest seems to be justified in these situations.
Low cell dose from an adult donor or the use of marrowtoxic drugs after transplant constitutes factors that place patients at risk of graft failure, but are unknown at the time when conditioning is initiated. In this study, almost all patients who required the use of backup marrow had risk factors for graft failure identifiable before transplantation. Several of these patients in this study preceded the refinements in histocompatibility testing that have improved donor-recipient matching. The use of well-matched adult donors, unmanipulated hematopoietic cells, peripheral blood in non-myeloablative transplants, and more stringent HLA-matching and cell dose requirements in cord transplants can minimize the risk of graft failure and the need for stored cells. Still, partially matched or mismatched marrow, or cord blood sometimes provides the best source of hematopoietic cells. In these instances, backup autologous harvest is a reasonable and potentially life-saving precaution. 
